JNJ-26990990 is a broad-spectrum anticonvulsant drug currently under development by Janssen Pharmaceutica as a second-generation followup to the marketed drug topiramate. It was designed to have the same anticonvulsant effects as topirimate but without the side effects associated with topiramate’s carbonic anhydrase inhibition.
This page contains content from the copyrighted Wikipedia article "JNJ-26990990"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
